Hepakain 300 Tablet contains Ursodeoxycholic Acid 300 mg, a hydrophilic bile acid used primarily in the treatment of various hepatobiliary disorders. It is indicated for the dissolution of cholesterol gallstones in patients with a functioning gallbladder and for the management of primary biliary cholangitis (PBC), a chronic autoimmune liver disease characterized by progressive destruction of intrahepatic bile ducts. Ursodeoxycholic Acid acts by reducing the cholesterol content of bile, thereby decreasing cholesterol saturation and promoting the gradual dissolution of cholesterol-rich gallstones. Additionally, it exerts cytoprotective effects on hepatocytes by stabilizing cell membranes, reducing bile acid-induced apoptosis, and improving bile flow. Hepakain 300 is administered orally, with dosage tailored according to the specific condition and patient response, typically ranging from 10 to 15 mg/kg/day divided into two or three doses. Common adverse effects include mild gastrointestinal disturbances such as diarrhea, nausea, and abdominal discomfort. Caution is advised in patients with complete biliary obstruction or acute cholecystitis. Regular monitoring of liver function tests is recommended during therapy to assess efficacy and detect potential hepatotoxicity. Hepakain 300 Tablet should be used under medical supervision to ensure optimal therapeutic outcomes.